The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The predictive value of HY antibodies for chronic graft-versus-host disease

Jan 17, 2019

It has been shown that antibodies targeting Y-chromosome encoded proteins (HY antibodies), detected 3 months post-transplant, in male hematopoietic stem cell transplantation (HSCT) recipients, who were transplanted from a female donor (FM), are significantly associated with chronic graft-versus-host disease (cGvHD) development, higher non-relapse mortality (NRM) rates, and poor overall survival (OS). 1,2In a letter to the editor of Haematologica, publishedonline on 17 January 2019, Jed Paulfrom Stanford University School of Medicine, Stanford, USA, et al. reported data from a multicenter, retrospective cohort study on HY antibody levels in patients undergoing transplantation to determine the correlation between higher levels of HY antibodies and cGvHD development. 3

Patients and methods

  • N = 234 patients
  • Plasma or serum samples were collected at 3-months and 1-year post-transplant
  • Antibodies were quantified against the five most informative HY antigens: DBY, UTY2, ZFY, RPS4Y, and EIF1AY
  • Data were collected from clinical trials that used cGvHD development as their study endpoints
  • HY antibody seropositivity threshold was set with a control group of n = 60 paired sera and EDTA plasma samples from healthy male blood donors

Key findings

  • Patients with antibodies against DBY had a 2.3-fold higher frequency in the 171 cGvHD patients versusthe 63 non-cGvHD patients, P= 0.045
  • Future cGvHD patients had a higher chance for HY seropositivity, however, this parameter is only predictive for cGvHD development 6–12 months later
  • NIH cGvHD severity was available for 79 clinical trial patients
  • 3-month DBY seropositivity was significantly predictive for severe cGvHD, P= 0.021
  • HY score was established in previous studies: the cumulative number of HY antibody seropositivities for a given sample
  • The HY score was found to be the most significant predictor of cGvHD development
  • If the HY score is > 1 at 3 months, it was predictive for cGvHD severity, P= 0.039
  • A HY score > 2 was found to be a strong predictor of cGvHD development: OR = 3.63, P= 0.027
  • Anti-DBY antibodies detected at 3-months correlated with cGvHD development: OR = 2.78, P= 0.053
  • N = 185 patients survived the first year after transplantation
    • N = 44 patients never developed cGvHD
    • N = 141 developed cGvHD during this period of time
  • 1-year HY score > 1 correlated with a 1.6-fold increase in cGvHD development, P= 0.029

In conclusion, this study evaluating the predictive value of HY antibodies showed that the presence of HY antibodies at 3 months post-transplant predicts cGvHD development. The authors added that “the 3-month HY score has its greatest utility in predicting which patients are more likely to develop severe cGvHD. As such, HY scoring at 3 months could identify patients at high risk for cGvHD prevention trials.”

  1. Nakasone H. et al. Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood. 2015 May 14; 125(20):3193-3201. DOI: 10.1182/blood-2014-11-613323.
  2. Miklos D.B. et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood. 2004 Jan 1; 103(1):353–359. DOI: 10.1182/blood-2003-03-0984.
  3. Paul J. et al. A confirmation of chronic graft-versus-host disease prediction using allogeneic HY antibodies following sex-mismatched hematopoietic cell transplantation. Haematologica. 2019 Jan 17. DOI: 10.3324/haematol.2018.199646. [Epub ahead of print].